Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept

Fig. 2

Clinical and MRI variables at WD and associated ORs for flare versus no flare. Data are shown for flare versus no flare at A WD+6mo and B WD+12mo. Data from WD were standardized (mean equal to zero and SD equal to one). Vertical line indicates limit of effect: positive data indicate effect, negative data or data that cross 1 indicate absence of effect. ORs (per one unit) and P values are from a univariate logistic regression model with scores at WD as the independent variables and flare at WD+6mo and WD+12mo as the dependent variable; bold P values indicate statistical significance. *HAQ-DI: n = 94 for flare at WD+6mo and n = 65 at WD+12mo; pain: n = 94 for flare at WD+6mo and n = 66 at WD+12mo; MRI: n = 92 for flare at WD+6mo and n = 63 at WD+12mo. †Synovitis score + edema score. ‡Synovitis score + 2x edema score. §HAQ-DI: n = 107 for flare at WD+6mo and n = 52 at WD+12mo; pain: n = 107 for flare at WD+6mo and n = 52 at WD+12mo; MRI: n = 103 for flare at WD+6mo and n = 52 at WD+12mo. OR odds ratio. See Fig. 1 for other definitions

Back to article page